Regeneron counsel exercises options on 12,282 shares

REGENERON PHARMACEUTICALS, INC.

Rhea-AI Filing Summary

REGENERON PHARMACEUTICALS, INC. (REGN) reported insider equity transactions by Joseph J. LaRosa, EVP General Counsel and Secretary. On 2026-08-19, he exercised a non-qualified stock option for 12,282 shares of common stock at an exercise price of $381.92 per share, from an award that vested in four equal annual installments commencing one year after grant. He acquired 12,282 common shares upon exercise and 9,019 shares of common stock at $830.15 per share were delivered or withheld for payment of exercise price or tax liability. Following the transaction, he directly held 12,283 non-qualified stock options expiring on 2026-12-16 and indirect common stock holdings of 3,402 shares via a 2024 GRAT, 5,407 shares via a 2025 GRAT, and 413 shares through a 401(k) plan.

Insider Trade Summary

12,282 shares exercised/converted

Exercise 6 txns

Insider LAROSA JOSEPH J

Role EVP General Counsel and Secret

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (right to buy) F1	12,282	$0.00	$0.00
Exercise	Common Stock	12,282	$381.92	$4.69M
Exercise Price or Tax Liability	Common Stock	9,019	$830.15	$7.49M
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 12,283 contracts (Direct); Common Stock — 36,373 shares (Direct); Common Stock — 3,402 shares (Indirect, By 2024 GRAT); Common Stock — 5,407 shares (Indirect, By 2025 GRAT); Common Stock — 413 shares (Indirect, By 401(k) Plan)

Footnotes (1)

1. F1. The stock option award vested in four equal annual installments, commencing one year after the date of grant.

Key Figures

Options exercised: 12,282 shares Option exercise price: $381.92 per share Shares delivered/withheld for exercise price or tax liability: 9,019 shares at $830.15 per share +5 more

8 metrics

Options exercised 12,282 shares Non-qualified stock option exercise on 2026-08-19

Option exercise price $381.92 per share Non-qualified stock option on REGN common stock

Shares delivered/withheld for exercise price or tax liability 9,019 shares at $830.15 per share Common stock used in connection with option exercise

Remaining non-qualified stock options 12,283 options Directly held after the reported transactions

Option expiration date 2026-12-16 Non-qualified stock option on REGN common stock

Indirect holding by 2024 GRAT 3,402 shares REGN common stock held indirectly

Indirect holding by 2025 GRAT 5,407 shares REGN common stock held indirectly

Indirect holding by 401(k) Plan 413 shares REGN common stock held through retirement plan

Key Terms

Non-Qualified Stock Option, Grantor Retained Annuity Trust (GRAT), 401(k) Plan, Payment of exercise price or tax liability

4 terms

Non-Qualified Stock Option financial

"security_title: "Non-Qualified Stock Option (right to buy)""

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

Grantor Retained Annuity Trust (GRAT) financial

"nature_of_ownership: "By 2024 GRAT" and "By 2025 GRAT""

401(k) Plan financial

"nature_of_ownership: "By 401(k) Plan""

A 401(k) plan is a workplace retirement account that lets employees set aside part of their pay into a tax-advantaged savings pot, often with employers adding matching contributions — like a workplace piggy bank for future income. It matters to investors because the amount people save and how employers fund these plans influence consumer spending, corporate payroll costs and the flow of money into financial markets, which can affect stock prices and company valuations.

Payment of exercise price or tax liability financial

"transaction_code_description for code F transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did REGN executive Joseph J. LaRosa report in this Form 4?

He exercised a non-qualified stock option for 12,282 REGN shares at $381.92 per share, acquired 12,282 common shares, and had 9,019 shares delivered or withheld at $830.15 per share for payment of exercise price or tax liability.

How many Regeneron (REGN) options does Joseph J. LaRosa hold after the transaction?

After the transaction, Joseph J. LaRosa held 12,283 non-qualified stock options on REGN common stock, with an expiration date of 2026-12-16, as reported in the Form 4.

What shares were used to cover exercise price or taxes in the REGN Form 4?

A total of 9,019 shares of REGN common stock, valued at $830.15 per share, were delivered or withheld for payment of exercise price or tax liability in connection with the stock option exercise.

What indirect REGN share holdings does Joseph J. LaRosa report?

He reports indirect holdings of REGN common stock of 3,402 shares by a 2024 GRAT, 5,407 shares by a 2025 GRAT, and 413 shares held through a 401(k) plan.

How did the exercised REGN option held by Joseph J. LaRosa vest?

The non-qualified stock option award vested in four equal annual installments, commencing one year after the date of grant, according to the footnote in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/21/2026 - 04:01 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LAROSA JOSEPH J

(Last) (First) (Middle)

777 OLD SAW MILL RIVER ROAD

(Street)

TARRYTOWN NEW YORK 10591

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP General Counsel and Secret

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2026		M		12,282	A	$381.92	45,392	D
Common Stock	08/19/2026		F		9,019	D	$830.15	36,373	D
Common Stock								3,402	I	By 2024 GRAT
Common Stock								5,407	I	By 2025 GRAT
Common Stock								413	I	By 401(k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$381.92	08/19/2026		M			12,282	(1)	12/16/2026	Common Stock	12,282	$0.0	12,283	D

Explanation of Responses:

1. The stock option award vested in four equal annual installments, commencing one year after the date of grant.

	/s/ Joseph LaRosa	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)